Study drug for HER2-positive advanced cancers
Part of Cancer, Digestive system, Skin clinical trials.
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is a solid tumor with HER2 testing showing HER2-positive or low HER2 results (based on specific lab patterns).
- If you have hormone-receptor–positive breast cancer, you must have already tried a CDK4/6 inhibitor before joining.
- Your blood counts and basic labs must be high enough (platelets ≥75,000, hemoglobin ≥9, neutrophils ≥1,000).
- Your kidneys and liver function must meet safety cutoffs (creatinine clearance >45; limits on AST/ALT and bilirubin).
- You must be well enough to do daily activities (ECOG 0–1, or similar Karnofsky score).
- You must not have lung inflammation (pneumonitis/ILD) that needed steroids, and you may need stable breathing and eye health; you also must not wear contact lenses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (KJ015) for people with solid tumors that have a protein called HER2. It’s for patients whose cancer has continued to grow despite previous treatments, and who are relatively well overall.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests a new drug, SKB103, for people with HER2-negative breast cancer that has not responded to standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called ES2B-C001, with or without an adjuvant, to see if it is safe for people with HER2-positive breast cancer that has spread and has not responded to previous treatments.
This study tests an investigational drug for people with certain advanced cancers that have not responded to other treatments. It may stop the cancer from growing by targeting a marker found on some tumor cells.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.